

Fig 1. Docetaxel PK profile in representative patient with normal liver function (\square) and patient with elevated hepatic enzymes (\blacksquare). Lines denote model predictions after Bayesian estimation.




Fig 2. Docetaxel population PK profile in a subset of 254 patients.



Fig 3. Model-predicted probability of febrile neutropenia as a function of CLf for a patient with median AAG. Reference vertical lines denote normal CL (CLf = 1) and 50% reduced CL (CLf = 2).

DOCETAXEL - LUNG

Survival




Figure 4: survival curves in NSCLC patients with low (≤ 1.11 g/L, —), intermediate (1.12 to 1.84 g/L, ----) and high (≥ 1.85 , -•-•-) baseline AAG (/censored observation)